Satellite tracker Spaceflux reaches lift-off with £5m funding boost
Sky News understands that Spaceflux, which was founded three years ago, has secured the injection of capital in a round led by the UK Innovation & Science Seed Fund (UKI2S), which is managed by Future Planet Capital, as well as Foresight Group and Blackfinch Ventures.
Seraphim Space, the listed specialist investor in space-related companies, is also contributing funding.
Money blog: Renowned chef thinks luxury item should be wiped off menus
Spaceflux uses artificial intelligence and optical sensors to track satellites and debris across all orbits, with its daylight tracking capability meaning it can expand the observation window beyond night-time operations.
Its provision of space situational awareness technologies is in growing demand amid warnings that a week-long disruption to satellite navigation could incur a £7.6bn hit to the UK economy.
In a statement to Sky News, Marco Rocchetto, CEO and co-founder of Spaceflux, said: "As space becomes increasingly essential to our economy, environment and daily lives, it is also becoming more congested and contested.
"This investment strengthens our ability to protect satellite technology that delivers crucial insights to Earth around the clock, reducing collision risks, and supporting a safer, more sustainable space environment for future generations".
The valuation at which the funding was being committed was unclear on Thursday.
Spaceflux, which serves government and commercial customers, has been the exclusive provider of geostationary satellite tracking for the Ministry of Defence and UK Space Agency since 2023.
Read more on Sky News:
Alex Leigh, an investment director at UKI2S, said: "This investment marks a significant step in the convergence of defence and space, where dual-use technologies are becoming increasingly important to UK capability.
"Spaceflux's technology offers critical insights to help monitor and safeguard orbital assets - supporting both national security and the wider commercial ecosystem.
"The company is well-positioned to scale its impact and meet the needs of customers navigating an increasingly complex space environment."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Tempus AI Raises Outlook, CEO Cites Faster-Than-Expected Growth And Improved Margins
Tempus AI Inc. (NASDAQ:TEM) reported second-quarter financial results Friday. The AI-focused precision medicine and patient care company reported a second-quarter adjusted loss of 22 cents per share, beating analyst estimates for a loss of 24 cents per share. Tempus AI reported quarterly revenue of $314.64 million, beating the consensus estimates of $296.85 million. Revenue increased 89.6% year-over-year. Genomics contributed $241.8 million in revenue in the quarter, growing 115.3% year over testing (Tempus genomics) delivered $133.2 million of revenue, up 32.9%, with approximately 26% volume growth versus 20% last quarter. Hereditary testing sales (Ambry genetics) reached $97.3 million, up 33.6% year-over-year on a pro forma basis with approximately 32% volume growth. Revenue from Data and services totaled $72.8 million, delivering 35.7% growth versus the second quarter of 2024, led by Insights (data licensing), which grew 40.7% year-over-year. Adjusted EBITDA of ($5.6 million) in the second quarter of 2025 compared to ($31.2 million) in the second quarter of 2024, an improvement of $25.6 million year-over-year. View more earnings on TEM 'The business is performing well with revenues and margins growing faster than expected, contributing to our continued improvement in adjusted EBITDA on a year-over-year basis,' said Eric Lefkofsky, Founder and CEO of Tempus. 'We saw significant re-acceleration of our clinical volumes, which grew 30% in the quarter, as we delivered more than 212,000 NGS tests,' Lefkofsky said in a statement on Friday. Database Update Through more than 4,500 integrations, Tempus said it connected to more than 40 million clinical patient records, with around 9 million de-identified and ingested, spanning approximately 1.1 billion healthcare documents, a significant percentage of which are connected to the around 4 million samples the company has sequenced. As a result, the company's database stands at over 350 petabytes of connected clinical and molecular data. Tempus AI ended the quarter with $293.0 million in cash and marketable securities, an improvement of around $70 million over last quarter. Outlook Tempus AI increased its guidance and expects a full year of 2025 revenue of approximately $1.26 billion for the consolidated business, representing approximately 82% annual growth, compared to the consensus of $1.25 billion. Earlier, the company expected revenue between $1.24 billion and $1.25 billion for its consolidated Tempus and Ambry Genetics business. The company reaffirms full-year 2025 adjusted EBITDA of $5 million, an improvement of approximately $110 million over 2024. Tempus AI received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ejection fraction software in July. Tempus said the FDA granted it 510(k) clearance for its Tempus ECG-Low EF software, which uses AI to identify patients with a potential left ventricular ejection fraction. Price Action: Tempus AI shares were up 5.79% after hours, trading at $55.21 at the time of publication on Tuesday. Read Next:Photo by Piotr Swat via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Tempus AI Raises Outlook, CEO Cites Faster-Than-Expected Growth And Improved Margins originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Yahoo
13 minutes ago
- Yahoo
Liverpool's clever new tactic to FORCE Alexander Isak transfer
Liverpool appear to have a new strategy to sign Alexander Isak. It's a clever tactic that might just work. Liverpool are eager to sign Alexander Isak this summer but Newcastle United aren't making it easy. For whatever reason, they're not keen to lose their star player. Making things worse is the fact that Newcastle have not found a suitable replacement. Or even a replacement of any kind - an unsuitable replacement would be an upgrade at this stage. Shop the LFC Store LFC x adidas Shop the home range today! LFC x adidas Shop the goalkeeper range today LFC x adidas Shop the new adidas range today! 🔴 Shop the LFC 2025/26 adidas home range The Magpies have tried and failed to sign several strikers in this window, including Hugo Ekitiké. Their pursuit of Benjamin Sesko is the latest to end in failure as he prepares to join Manchester United. It creates an awkward situation. Isak very much wants to leave and is pushing for an exit. Newcastle are very aware of this and all reports suggest he can leave if they find that replacement. They're not keen to have an upset player on their books. The money would be far preferable if (there's that word again) they're able to use it. 🔴 Shop the LFC 2025/26 adidas away range Liverpool try a new tactic Which brings us to Liverpool's pursuit of Bradley Barcola. L'Équipe claim there's strong interest there in getting a move done this summer. Any deal would cost around €100m as Paris Saint-Germain rate the player highly. Not an easy deal, then, but a possible one as Barcola isn't currently one of the leading stars at PSG. But this simply must be the Isak money. There are no reports anywhere suggesting Liverpool could sign both and that the money is there for two €100m+ transfers. Which means this is actually a pressure tactic. At least initially. It's a message to Newcastle that if they really do want the money, they'll need to open the door further. Otherwise they risk losing out entirely and finding themselves in a much weaker position down the line.
Yahoo
13 minutes ago
- Yahoo
Al Gore's Generation Investment Management Reduces Amazon.com Inc by 3.8% in Q2 2025
Exploring the Strategic Moves of a Sustainability-Focused Investment Firm Introduction to Al Gore (Trades, Portfolio) and Generation Investment Management Warning! GuruFocus has detected 7 Warning Sign with MSFT. Al Gore (Trades, Portfolio), the former Vice President of the United States, is renowned for his environmental advocacy and commitment to sustainable development. In 2004, he co-founded Generation Investment Management alongside David Blood. This London-based firm is dedicated to long-term investing with a focus on sustainability, integrating economic, social, and environmental considerations into its investment strategies. Generation Investment Management serves a diverse clientele, including pooled investment vehicles and pension plans, and offers a range of products such as Global Equity and Climate Solutions. The firm emphasizes a systematic approach to global challenges, identifying key drivers of change like climate change and resource scarcity, which can significantly impact a company's performance. Summary of New Buy Al Gore (Trades, Portfolio) added a total of three stocks to his portfolio in the second quarter of 2025. The most significant addition was IDEXX Laboratories Inc (NASDAQ:IDXX), with 567,322 shares, accounting for 1.93% of the portfolio and a total value of $304.28 million. The second largest addition was West Pharmaceutical Services Inc (NYSE:WST), consisting of 1,165,777 shares, representing approximately 1.62% of the portfolio, with a total value of $255.07 million. The third largest addition was Moody's Corp (NYSE:MCO), with 271,074 shares, accounting for 0.86% of the portfolio and a total value of $135.97 million. Key Position Increases Al Gore (Trades, Portfolio) also increased stakes in a total of seven stocks. The most notable increase was in Danaher Corp (NYSE:DHR), with an additional 1,787,522 shares, bringing the total to 4,965,646 shares. This adjustment represents a significant 56.24% increase in share count, a 2.25% impact on the current portfolio, with a total value of $980.91 million. The second largest increase was in Visa Inc (NYSE:V), with an additional 660,362 shares, bringing the total to 1,373,485. This adjustment represents a significant 92.6% increase in share count, with a total value of $487.66 million. Summary of Sold Out Al Gore (Trades, Portfolio) completely exited four holdings in the second quarter of 2025. Notably, he sold all 635,999 shares of Mastercard Inc (NYSE:MA), resulting in a -2.11% impact on the portfolio. Additionally, he liquidated all 755,325 shares of Waters Corp (NYSE:WAT), causing a -1.68% impact on the portfolio. Key Position Reduces Al Gore (Trades, Portfolio) also reduced positions in 23 stocks. The most significant change was a reduction in Inc (NASDAQ:AMZN) by 3,309,515 shares, resulting in a -65.77% decrease in shares and a -3.8% impact on the portfolio. The stock traded at an average price of $197.77 during the quarter and has returned 18.24% over the past three months and 1.70% year-to-date. Another notable reduction was in Becton Dickinson & Co (NYSE:BDX) by 2,537,140 shares, resulting in a -47.9% reduction in shares and a -3.51% impact on the portfolio. The stock traded at an average price of $184.01 during the quarter and has returned 12.97% over the past three months and -16.40% year-to-date. Portfolio Overview As of the second quarter of 2025, Al Gore (Trades, Portfolio)'s portfolio included 37 stocks. The top holdings were 15.93% in Microsoft Corp (NASDAQ:MSFT), 8.05% in Charles Schwab Corp (NYSE:SCHW), 7.65% in MercadoLibre Inc (NASDAQ:MELI), 6.24% in Danaher Corp (NYSE:DHR), and 4.84% in Steris PLC (NYSE:STE). The holdings are mainly concentrated in seven of the 11 industries: Technology, Healthcare, Consumer Cyclical, Financial Services, Industrials, Communication Services, and Real Estate. This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
